A Comprehensive Look at Abemaciclib's Advantages and Applications

CAT NO: - A1840000

CAS NO: - 1231929-97-7

Abemaciclib is chemically described as N-(5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine. It's molecular formula and molecular weight is C27H32F2N8 and 506.59 g/mol respectively. Abemaciclib is approved by the U.S. Food and Drug Administration (FDA) in September 2017. It is sold under the brand name Verzenio

Applications:- 

Abemaciclib is a medication used in the treatment of certain types of cancer, particularly breast cancer. It is also being investigated in clinical trials for its potential efficacy in treating other types of cancer, such as lung cancer, pancreatic cancer, and other solid tumors.

These trials aim to evaluate the safety and efficacy of abemaciclib either as a standalone treatment or in combination with other therapies. Abemaciclib is being studied in clinical trials as adjuvant therapy, which is treatment given after the primary treatment (such as surgery) to lower the risk of cancer recurrence.

Advantages:-

Targeted Therapy: - Abemaciclib is a targeted therapy that specifically inhibits cyclin-dependent kinase 4 and 6 (CDK4/6). By targeting these enzymes, abemaciclib interferes with the cell cycle progression of cancer cells, particularly those in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Improved Progression-Free Survival: Clinical trials have demonstrated that abemaciclib, when used in combination with endocrine therapy (such as aromatase inhibitors or fulvestrant), can significantly improve progression-free survival (PFS) in patients with HR+/HER2- advanced or metastatic breast cancer compared to endocrine therapy alone.

Oral Administration: Abemaciclib is administered orally in the form of tablets, making it convenient for patients to take at home. Potential for Combination Therapy: Abemaciclib can be used in combination with other targeted therapies, such as other CDK4/6 inhibitors or immune checkpoint inhibitors, as well as with traditional chemotherapy agents.

Investigational Applications: Beyond breast cancer, abemaciclib is being investigated in clinical trials for its potential efficacy in treating other types of cancer, such as lung cancer, pancreatic cancer, and other solid tumors. These ongoing trials may expand the range of applications for abemaciclib in the future.

Mechanism:-

Abemaciclib is a medication that belongs to a class of drugs known as cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Its primary mechanism of action involves inhibiting the activity of CDK4 and CDK6 enzymes.

These enzymes play a crucial role in regulating the cell cycle, specifically the transition from the G1 phase to the S phase, where DNA synthesis occurs. Common side effects includes Diarrhoea, Fatigue, Nausea, & etc.

Some of the Impurities of Abemaciclib are as follows:-

Check All Products